{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:33:19Z","timestamp":1790098399621,"version":"4.0.1"},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,11,13]],"date-time":"2007-11-13T00:00:00Z","timestamp":1194912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Topical immunotherapy with diphencyprone (DPCP) is considered the most effective treatment of alopecia areata (AA).<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To assess the efficacy of DPCP in the treatment of extensive or long\u2010lasting AA in Greek patients.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Sixty\u2010four patients with extensive and\/or long\u2010lasting AA were sensitized with 2% diphencyprone. During each weekly subsequent visit, patients were treated with gradually denser concentrations adjusted in order to maintain erythema and itch on the patient's scalp for 48\u00a0h. Patients\u2019 hair re\u2010growth was evaluated every 3\u00a0months for 2\u00a0years.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Forty\u2010five patients responded among the 54 completing therapy (83.3%). Initial response was observed 3.48\u00a0\u00b1\u00a01.05\u00a0months after the initial treatment. Twenty patients among the responders achieved a grade 4 response, 15 patients achieved grade 3, 9 patients achieved grade 2, and 1 patient achieved a grade 1 response. The mean duration of treatment until maximum response was 6.14\u00a0\u00b1\u00a01.48\u00a0months. Thirty\u2010one patients (68.9%) had a relapse during follow\u2010up and were treated again. The only adverse event among patients completing therapy was contact dermatitis of the face or neck (9 of 54) that resolved after topical corticosteroid application within 7\u00a0days. Statistical analysis did not establish any association among duration of AA, age, gender, atopic diathesis, nail involvement and presence of thyroid antibodies with response to treatment.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Treatment of Greek patients with AA with diphencyprone presents high response rates similar to those reported by previous studies. The treatment is adequately tolerated by most of the patients, and they are willing to repeat it in cases of relapse.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2007.02411.x","type":"journal-article","created":{"date-parts":[[2007,11,15]],"date-time":"2007-11-15T19:23:57Z","timestamp":1195154637000},"page":"320-323","source":"Crossref","is-referenced-by-count":38,"title":["Alopecia areata: topical immunotherapy treatment with diphencyprone"],"prefix":"10.1111","volume":"22","author":[{"given":"G","family":"Avgerinou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Gregoriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Rigopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Stratigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Kalogeromitros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Katsambas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,11,13]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01727.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01781.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01592.x"},{"key":"e_1_2_6_5_2","first-page":"264","article-title":"Severe dermatitis caused by diphenylcyclopropenone","volume":"11","author":"Whittaker M.","year":"1972","journal-title":"Contact Dermatitis News Lett"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.109309"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.1.112"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70195-7"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb03230.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2340\/00015555642630","article-title":"Immunohistochemical analysis of Tcell subsets in the peribulbar and intrabulbar infiltrates in alopecia areata","volume":"64","author":"Perret C","year":"1984","journal-title":"Acta Dermatol Venereol"},{"key":"e_1_2_6_11_2","first-page":"1063","article-title":"Predictive model for immunotherapy of alopecia areata with diphencyprone","volume":"137","author":"Wiseman MC","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.00811.x"},{"key":"e_1_2_6_13_2","first-page":"723","volume-title":"Dermatology in Europe","author":"Avgerinou G","year":"1989"},{"key":"e_1_2_6_14_2","unstructured":"AvgerinouG VareltzidisA StratigosA FertakisH ToscaA.Adhesion molecules in the pathogenesis of alopecia areata. 3rd.Congress of the EADV Copenhagen Denmark 1993: Abstract P\u2010312."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2004.01138.x"},{"key":"e_1_2_6_16_2","first-page":"397","article-title":"Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA)","volume":"35","author":"Galadari I","journal-title":"Allerg Immunol (Paris)"},{"key":"e_1_2_6_17_2","unstructured":"ShapiroJ TanJ HoV AbbottF TronV.Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(18)30255-9"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1991.tb06064.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2004.09.008"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01750.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01676.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2007.02411.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2007.02411.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T14:54:24Z","timestamp":1697036064000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2007.02411.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,13]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1111\/j.1468-3083.2007.02411.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2007.02411.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,13]]}}}